
Solaris Resources Inc. (CVE:SLS – Free Report) – Research analysts at HC Wainwright boosted their FY2026 earnings estimates for Solaris Resources in a research note issued to investors on Wednesday, November 18th. HC Wainwright analyst H. Ihle now forecasts that the company will earn ($0.19) per share for the year, up from their previous forecast of ($0.20).
Solaris Resources Price Performance
Shares of SLS stock opened at C$6.15 on Friday. The firm has a fifty day moving average of C$6.15 and a 200-day moving average of C$6.15. Solaris Resources has a 12-month low of C$1.38 and a 12-month high of C$7.09.
Solaris Resources Company Profile
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer.
Recommended Stories
- Five stocks we like better than Solaris Resources
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Solaris Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solaris Resources and related companies with MarketBeat.com's FREE daily email newsletter.
